- Texas man arrested for powder-letter hoax
- Islamic State opens ‘marriage bureau’ for single jihadists
- Drone almost blocks California firefighting planes
- Tornado rips off roofs, downs trees near Boston
- GOP: Environmental rules keeping agents from accessing border
- John Kerry: Millions displaced by religious fighting in 2013
- Federal appeals court rules against Virginia’s gay marriage ban
- White House says Russia ‘losing’ war in Ukraine
- Hamas turns to North Korea for weapons deal, Iran for money
- Syrian casualties surge as jihadis consolidate
Endocyte surges on news for cancer drug
Question of the Day
NEW YORK (AP) - Shares of Endocyte nearly doubled in value Friday after European Union regulators said the company’s drug Vynfinit should be approved as a treatment for ovarian cancer, and Endocyte said the drug helped slow the progression of lung cancer in a midstage trial.
The stock reached an all-time high of $33.70, and closed up $13.53, or 92 percent, at $28.17.
Endocyte and its partner Merck said a panel of European Union regulatory advisers recommended that Vynfinit be approved as a treatment for recurrent ovarian cancer in adult women whose disease isn’t responding to platinum-based chemotherapy. The panel’s recommendation also covers two imaging agents that are intended to help identify patients who could be helped by Vynfinit.
Vynfinit, or vintafolide, is designed to target a receptor that appears on cancer cells but doesn’t exist on most other cells. The drug is intended to be used with the chemotherapy treatment doxorubicin.
EU regulators should make a final decision on the drug within three months, said Cowen and Co. analyst Simos Simeonidis. He expects them to approve Vynfinit and said the drug should be launched shortly thereafter. He rates Endocyte shares “Outperform.”
The companies also said patients with lung cancer lived longer or saw a slower progression of their disease if they were treated with Vynfinit and doxorubicin. The midstage trial compared those drugs to standard treatment in 199 patients with non-small cell lung cancer.
This would be the first approved drug for Endocyte Inc., based in West Lafayette, Ind. Merck and Endocyte announced a partnership in April 2012. Merck paid Endocyte $120 million upfront, and Endocyte stands to receive more than $1 billion if Vynfinit is successfully developed as an approved treatment for multiple types of cancer.
Shares of Merck & Co. lost 93 cents to finish at $54.66.
TWT Video Picks
By David Keene
Allowing states to innovate could reduce dependency on bureaucracy
- D.C. seeks to stay judge's order allowing gun owners to carry in public
- Hillary Clinton: Forget Obama, George W. Bush made her 'proud to be an American'
- Iraqi Christians rally at White House: 'Obama, Obama, where are you?'
- Illegal immigrants demand representation in White House meetings
- White House defends Kerry failure to broker Middle East cease-fire
- Tennessee Gov. Haslam slams White House for secret dump of illegals in his state
- Border surge puts Obama legacy on immigration at stake
- Federal appeals court rules against Virginia's gay marriage ban
- Federal judge rules D.C. ban on handguns in public is unconstitutional
- White House says Russia 'losing' war in Ukraine
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq